Suvi Kalliokoski

Suvi Kalliokoski

Auto-generated profile, based on publicly available information

Suvi Kalliokoski

Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSuvi Kalliokoski
Suvi Kalliokoski
ASAna-Marija Sulic
Ana-Marija Sulic
IKIlma R. Korponay-Szabó
Ilma R. Korponay-Szabó
ZSZsuzsa Szondy
Zsuzsa Szondy
RFRafael Frias
Rafael Frias
SCSergio Caja
Sergio Caja
A characteristic feature of celiac disease is the presence of circulating autoantibodies targeted against transglutaminase 2 (TG2), reputed to have a function in angiogenesis. In this study we investigated whether TG2-specific autoantibodies derived from celiac patients inhibit angiogenesis in both ex vivo and in vivo models and sought to clarify the mechanism behind this phenomenon. We used the ex vivo murine aorta-ring and the in vivo mouse matrigel-plug assays to address aforementioned issues. We found angiogenesis to be impaired as a result of celiac disease antibody supplementation in both systems. Our results also showed the dynamics of endothelial cells was affected in the presence of celiac antibodies. In the in vivo angiogenesis assays, the vessels formed were able to transport blood despite impairment of functionality after treatment with celiac autoantibodies, as revealed by positron emission tomography. We conclude that celiac autoantibodies inhibit angiogenesis ex vivo and in vivo and impair vascular functionality. Our data suggest that the anti-angiogenic mechanism of the celiac disease-specific autoantibodies involves extracellular TG2 and inhibited endothelial cell mobility.

9 August 2016 in Amino Acids
Verified
Journal Article
Closed access
PDF file
SKSuvi Kalliokoski
Suvi Kalliokoski
Victoria Ortín PiquerasVictoria Ortín Piqueras
Victoria Ortín Piqueras
RFRafael Frías
Rafael Frías
ASAna-Marija Sulic
Ana-Marija Sulic
JMJuha A. E. Määttä
Juha A. E. Määttä
KLKatri Lindfors
Katri Lindfors

24 May 2012 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
KLKatri Lindfors
Katri Lindfors
MLMarja-Leena Lähdeaho
Marja-Leena Lähdeaho
SKSuvi Kalliokoski
Suvi Kalliokoski
KKKalle Kurppa
Kalle Kurppa
PCPekka Collin
Pekka Collin
KKKatri Kaukinen
Katri Kaukinen
Ingestion of dietary gluten in wheat, rye and barley by celiac patients leads to small-bowel mucosal villous atrophy, crypt hyperplasia and massive inflammation, often coupled with clinical symptoms and signs. Currently, the only effective treatment is a strict life-long gluten-free diet excluding all gluten-containing food products. In view of the extremely restricted nature of the diet, new treatment options would clearly be desirable. The improved understanding of celiac disease pathogenesis has enabled researchers to suggest alternative strategies to treat the disorder. This review covers current approaches toward developing an appropriate drug and discusses the possible problems associated with these approaches. Phase II clinical trials are already ongoing to test the efficacy of novel alternative treatments for celiac disease. Before any of the candidates can enter Phase III trials, however, researchers must develop novel reliable non-invasive surrogate markers for intestinal injury and disease activity which also accurately reflect patient-related outcomes. Any novel medication for celiac disease should be as effective and safe as the gluten-free diet, and this constitutes a challenge for drug development. It is thus likely that the first medication entering the market will be supplementary to rather than substitute the gluten-free diet.

12 September 2014 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
SKSuvi Kalliokoski
Suvi Kalliokoski
SCSergio Caja
Sergio Caja
RFRafael Frias
Rafael Frias
KLKaija Laurila
Kaija Laurila
OKOuti Koskinen
Outi Koskinen
KLKatri Lindfors
Katri Lindfors

1 September 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SKSuvi Kalliokoski
Suvi Kalliokoski
EMEriika Mansikka
Eriika Mansikka
AKAndrea de Kauwe
Andrea de Kauwe
HHHeini Huhtala
Heini Huhtala
PSPäivi Saavalainen
Päivi Saavalainen
KLKatri Lindfors
Katri Lindfors

6 January 2014 in PLOS ONE
Verified
Journal Article
Open access
SKSuvi Kalliokoski
Suvi Kalliokoski
ASAna-Marija Sulic
Ana-Marija Sulic
IKIlma R. Korponay-Szabã³
Ilma R. Korponay-Szabã³
ZSZsuzsa Szondy
Zsuzsa Szondy
RFRafael Frias
Rafael Frias
SCSergio Caja
Sergio Caja